Welcome to our wonderful, learned, positive and supportive

New Post Public Reply Private Reply Replies (1) Message Board
DJknows invisioner #40667
1,120
Welcome to our wonderful, learned, positive and supportive CytoDyn group!

First off, with all the Covid-19 illness/deaths in the world and apparent impossibility of manufacturing or producing the potential multi-millions of vials needed in any kind of timely manner, odds are it's best to have several strong and truly healing drugs.

Quote:
The current world population is 7.8 billion as of June 2020 according to the most recent United Nations estimates elaborated by Worldometer.

https://www.worldometers.info/


With facts from the experts (doctors who've been and are dealing with Leron as I post this), I suspect Leronlimab will be among the top and the best to treat those getting sick and near dying from Covid-19. And those drugs that turn out sub-par are being and will be discovered.

The fundamentals of this drug and company are stellar... and the potential even moreso. HIV patients and their families the world over have likely been praying for a Leronlimab without even knowing there's anything like it. What we heard yesterday from Dr. Pourhassan is nothing short of miraculous once proven to all. Seems every day, our scientists find new and invaluable information... whether because we've been plagued with Covid-19 or otherwise.

Then we have the 23 cancers that have been identified for Leronlimab to tackle... when has anyone ever heard of this or the multitude of other major ailments to crush with just this one extraordinary medication (and almost nill side effects)... it's a weekly subcutaneous injection now but Dr. Patterson has said it could become monthly and what if one day another easier method of administering is produced... a pill ???

Dr. Pourhassan has repeatedly stated working WITH the FDA and even how this regulatory agency has given preferential treatment to CytoDyn during this Covid-19 process with them.

Yes it's depressing to even hear of death of strangers and humankind on this entire planet, much less deal with it within our own families and among our friends... but we, as investors or just folks who know about this company and Leronlimab ... should be so much more hopeful than the mega millions out there who do not know.

Finally, Leronlimab has already proven (at least in my mind) to be a life saver, an extraordinary medicine, a "homerun" ... even if human trial results are yet to come out.

As to finding info on CYDY , there's plenty available now ... and as an investor, keep the following in mind:

Quote:
Cytodyn has identified possible revenues:

Coronavirus of $9 billion
HIV of up to $12 billion
Breast Cancer of $60 billion


https://seekingalpha.com/article/4356732-cyto...terruption

What more can any 'penny' stock investor hope for or want... in this OTC gutter where there's 99.9% trash, CYDY is an absolute GEM!

It's all about what you know, your money and whether you believe...

Very best to you and all with CYDY !


















CytoDyn Inc (CYDY) Stock Research Links

CYDY Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

UBCF Extends Pink Bag Event for Breast Cancer Aid

Updated Category News Views 2

Community Need Drives Event Extension October in Jonesboro just got a bit more hopeful for breast cancer survivors—it's not just about awareness anymore; it's about action. The United Breast Cancer Foundation (UBCF) has decided to extend its popular Pink Bag free shopping event through October 30th. What spurred this decision? Well, the overwhelming community demand,...

Continue Reading
AI Tool circMAC Enhances MicroRNA Mapping on circRNAs

Updated Category News Views 3

Mapping the Complex Maze of MicroRNA on Circular RNAs Pusan National University's brainiacs have cooked up something spicy for the bioinformatics world. They've developed this snazzy AI tool, circMAC, to unravel microRNA binding mysteries on circular RNAs. 'Why’s this such a big deal?' you ask. Well, these loop-shaped critters, circRNAs, play a backstage role in gene...

Continue Reading
Podium Surges Past $150M in AI ARR Milestone

Updated Category News Views 3

A New Era for Podium When the brass at Podium made a gamble on AI, they didn't just try squeezing it into their old business model. Oh no, they launched what feels like a startup within their existing empire—no half-measures, just full-throttle ambition. Fast forward two and a half years, and they've racked up over $150 million in annual recurring revenue from these...

Continue Reading
Labcorp, FDA Collaborate to Tackle Drug Abuse Risks

Updated Category News Views 2

Rethinking How We Evaluate Drug Abuse Potential Sometimes, the finance world gets a peek into something that ain't just about the numbers on a screen, something with real stakes beyond the bulls and bears. Labcorp's just thrown its hat in with the FDA and Charles River Laboratories in a collaboration that goes beyond just lining pockets. They're setting up to dissect how...

Continue Reading
Vertice P2P Aims to Transform Procurement Efficiency

Updated Category News Views 9

Vertice Dives Deeper into the Procurement Game Grab a coffee and let's talk some procurement—one of the least sexy, yet utterly essential parts of any operation. Vertice's latest announcement is anything but mundane. They're spiraling deeper into the procurement universe with their new Procure-to-Pay (P2P) capability, a bold expansion from their Intake-to-Procure (I2P)...

Continue Reading
Cognizant AI Nexus Aims to Tame Enterprise AI Chaos

Updated Category News Views 5

AI Investments Without Returns: The Current Scenario Well, wouldn't you know it? Enterprises have sunk a fortune into AI, and they're wagging their fingers once more at the mounting bills with little to show for it. Play the investment game long enough, and it seems you'll find the numbers don't always rub together and make sparks. This familiar tune of over-budget...

Continue Reading
TransPerfect Launches College Bowl Game in Puerto Rico

Updated Category News Views 2

Puerto Rico Welcomes College Football with Open Arms Imagine kicking towards the goalposts while the ocean breeze kisses your face—yep, that's what's happening in Puerto Rico this December. TransPerfect, a heavyweight in language and tech solutions, is rolling out the red carpet for the inaugural TransPerfect San Juan Bowl, and it’s not just a game. It’s a bold step...

Continue Reading
Carrier Drops $600M on U.S. Manufacturing Boost

Updated Category News Views 3

A Mighty Move in Manufacturing Carrier Global Corporation's recent muscle-flexing is something rarer than a golden goose in today's market—a $600 million thrust into beefing up U.S. manufacturing and engineering. You can't help but wonder if this is overzealous optimism or a meticulously calculated power play. Clocks don't tick this loudly without good reason, of...

Continue Reading
Innventure Investors Alert: Securities Investigation Looms

Updated Category News Views 6

Innventure's Murky Waters Just when you think you've seen it all, stuff like this reminds you nothing's safe in the market. The law folks at Stranch, Jennings & Garvey, PLLC are sniffing around Innventure, Inc. (NASDAQ: INV) like bloodhounds to see if there's been some hoodwinking going on. We're talking questions about funny business with a data center deal between...

Continue Reading
Xona's $250M Raise: GPS Transformation Sparks Debate

Updated Category News Views 5

The Satellite Race Heats Up: Xona's Ambitious Leap Hold onto your hats, folks, because Xona's making headlines with a $250 million infusion. This ain't just pocket change—it's part of a rocket-fueled mission to upend the GPS landscape. Imagine a world where GPS is 100 times stronger. That's the pitch, and folks, it's got the market buzzing. Valuation Rocketing: Investor...

Continue Reading

Top 5 Most Recently Viewed Articles

osapiens Attracts $100 Million Investment, Solidifying Unicorn Status

Updated Category News Views 125

osapiens Secures Major Funding Round osapiens, a leading firm in enterprise software dedicated to encouraging sustainable growth, has recently announced a significant financial milestone. The company has secured an impressive US$ 100 million in a Series C funding round, spearheaded by Decarbonization Partners, a collaboration between BlackRock and Temasek. This newfound...

Continue Reading
Microsoft Teams Partners with Thrive Global for Enhanced Wellbeing

Updated Category News Views 167

Microsoft and Thrive Global Join Forces for Employee Wellbeing Microsoft has embarked on an inspiring journey by partnering with Thrive Global, a company that specializes in behavior change strategies aimed at enhancing overall wellbeing. This collaboration aims to integrate a range of wellbeing resources seamlessly into the daily operations of Microsoft Teams, making it...

Continue Reading
Coventry First Challenges Abacus Lawsuit Over Life Settlements

Updated Category News Views 420

Coventry First LLC Files Motion to Dismiss Lawsuit Coventry First LLC, along with Co-Founder and Executive Chairman Alan H. Buerger, is taking a decisive stand against the lawsuit filed by Abacus Global Management, Inc. This move comes in response to a claim that Coventry believes lacks merit, particularly in light of recent industry changes. Key Developments Around the...

Continue Reading
AbbVie Announces Significant Dividend Increase for Shareholders

Updated Category News Views 222

AbbVie Declares Quarterly Dividend The board of directors at AbbVie Inc. (NYSE: ABBV) has announced a quarterly cash dividend of $1.55 per share. This decision reflects the company's ongoing commitment to providing value to its shareholders through dependable and substantial dividend distributions. Details and Timeline for the Dividend The announced dividend will be paid...

Continue Reading
GitLab's 'Ultimate' Strategy Drives Adoption and Stock Upgrades

Updated Category News Views 77

GitLab's Growing Demand for 'Ultimate' GitLab Inc (NASDAQ: GTLB) has recently experienced a notable uptick in the adoption of its 'Ultimate' offering, according to industry expert insights. The stock saw a boost when analyst Mike Cikos from Needham raised its rating from Hold to Buy, setting a price target of $70. This optimistic outlook is backed by GitLab's continued...

Continue Reading